Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - dobutamine hydrochloride, quantity: 14.01 mg/ml (equivalent: dobutamine, qty 12.5 mg/ml) - injection, concentrated - excipient ingredients: sodium metabisulfite; hydrochloric acid; sodium hydroxide; water for injections - adults who require short-term treatment of cardiac failure secondary to acute myocardial infarction, or cardiac surgery.???

New Zealand - English - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - dobutamine hydrochloride 14.01 mg/ml equivalent to dobutamine 12.5 mg/ml - concentrate for injection - 12.5 mg/ml - active: dobutamine hydrochloride 14.01 mg/ml equivalent to dobutamine 12.5 mg/ml excipient: hydrochloric acid nitrogen sodium hydroxide sodium metabisulfite water for injection - dobutamine hydrochloride is indicated when inotropic support is necessary for the treatment of patients with hypoperfusion states in whom cardiac output is insufficient to meet circulatory demands. dobutamine hydrochloride is also indicated when inotropic support is required for the treatment of patients in whom abnormally increased ventricular filling pressures introduce the risk of pulmonary congestion and oedema. conditions which may precipitate such situations include the following hypoperfusion states: initially cardiac in origin a. acute heart failure 1. acute myocardial infarction 2. cardiogenic shock 3. following cardiac surgery 4. medicine-induced depression of cardiac contractility such as that which occurs in excessive ?- adrenergic receptor blockade. b. chronic heart failure 1. acute decompensation of chronic congestive heart failure 2. temporary inotropic support in advanced chronic congestive heart failure, as an adjunct to therapy with convention

New Zealand - English - Medsafe (Medicines Safety Authority)

max health limited - dobutamine hydrochloride 14 mg/ml equivalent to dobutamine 12.5 mg/ml, 250 mg dobutamine in 20 ml;   - concentrate for infusion - 12.5 mg/ml - active: dobutamine hydrochloride 14 mg/ml equivalent to dobutamine 12.5 mg/ml, 250 mg dobutamine in 20 ml   excipient: hydrochloric acid sodium metabisulfite water for injection - dobutamine hydrochloride is indicated when inotropic support is necessary for the treatment of patients with hypoperfusion states in whom cardiac output is insufficient to meet circulatory demands. dobutamine hydrochloride is also indicated when inotropic support is required for the treatment of patients in whom abnormally increased ventricular filling pressures introduce the risk of pulmonary congestion and oedema. conditions which may precipitate such situations include the following hypoperfusion states: initially cardiac in origin: a. acute heart failure acute myocardial infarction, cardiogenic shock, following cardiac surgery, medicine-induced depression of cardiac contractility such as that which occurs in excessive ?-adrenergic receptor blockade. b. chronic heart failure acute decompensation of chronic congestive heart failure, temporary inotropic support in advanced chronic congestive heart failure, as an adjunct to therapy with conventional oral inotropic agents, systemic vasodilators, and diuretics. initially noncardiac in origin: acute hypoperfusion states secondary to trauma, surgery, sepsis, or hypovolaemia when mean arterial pressure is above 70-mm hg and pulmonary capillary wedge pressure is 18-mm hg or greater, with inadequate response to volume repletion and increased ventricular filling pressure, low cardiac output secondary to mechanical ventilation with positive end-expiratory pressure (peep). paediatric population: dobutamine is indicated in all paediatric age groups (from neonates to 18 years of age) as inotropic support in low cardiac output hypoperfusion states resulting from decompensated heart failure, following cardiac surgery, cardiomyopathies and in cardiogenic or septic shock. dobutamine stress echocardiography: dobutamine hydrochloride may be used as a substitute for physical exercise in stress testing in the diagnosis of coronary artery disease. precautions apply (refer to data sheet).

Ireland - English - HPRA (Health Products Regulatory Authority)

claris lifesciences (uk) limited - dobutamine hydrochloride - concentrate for soln for inf - 12.5 mg/ml - adrenergic and dopaminergic agents

Ireland - English - HPRA (Health Products Regulatory Authority)

hospira uk limited - dobutamine hydrochloride - concentrate for soln for inf - 12.5 mg/ml - dobutamine

United States - English - NLM (National Library of Medicine)

hospira, inc. - dobutamine hydrochloride (unii: 0wr771djxv) (dobutamine - unii:3s12j47372) - dobutamine 12.5 mg in 1 ml - dobutamine injection, usp is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of adults with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. in patients who have atrial fibrillation with rapid ventricular response, a digitalis preparation should be used prior to institution of therapy with dobutamine hydrochloride. dobutamine hydrochloride is contraindicated in patients with idiopathic hypertrophic subaortic stenosis and in patients who have shown previous manifestations of hypersensitivity to dobutamine injection, usp solution.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - dobutamine hydrochloride, quantity: 14 mg/ml (equivalent: dobutamine, qty 12.5 mg/ml) - injection, concentrated - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections; sodium metabisulfite - adults who require short-term treatment of cardiac failure secondary to acute myocardial infarction, or cardiac surgery.

Israel - English - Ministry of Health

david margalit & co.ltd - dobutamine as hydrochloride - concentrate for solution for infusion - dobutamine as hydrochloride 12.5 mg/ml - dobutamine - dobutamine is indicated for patients who require a positive inotropic support in the short term treatment of adults with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures, especially when a low cardiac output is associated with raised pulmonary pressure.

Malta - English - Medicines Authority

mercury pharmaceuticals (ireland) limited 4045 kingswood road, city west business park, co, dublin, ireland - dobutamine - concentrate for solution for infusion - dobutamine 12.5 mg/ml - cardiac therapy

Ireland - English - HPRA (Health Products Regulatory Authority)

baxter holding b.v. - dobutamine - concentrate for solution for infusion - 12.5 milligram(s)/millilitre - adrenergic and dopaminergic agents; dobutamine